Rhythm Pharmaceuticals Stock Cash And Equivalents
| RYTM Stock | USD 56.12 0.64 1.15% |
Rhythm Pharmaceuticals fundamentals help investors to digest information that contributes to Rhythm Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Rhythm Stock. The fundamental analysis module provides a way to measure Rhythm Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Rhythm Pharmaceuticals stock.
Rhythm | Cash And Equivalents |
Rhythm Pharmaceuticals Company Cash And Equivalents Analysis
Rhythm Pharmaceuticals' Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current Rhythm Pharmaceuticals Cash And Equivalents | 235.6 M |
Most of Rhythm Pharmaceuticals' fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Rhythm Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Rhythm Cash And Equivalents Driver Correlations
Understanding the fundamental principles of building solid financial models for Rhythm Pharmaceuticals is extremely important. It helps to project a fair market value of Rhythm Stock properly, considering its historical fundamentals such as Cash And Equivalents. Since Rhythm Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Rhythm Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Rhythm Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
| Competition |
Rhythm Cash And Cash Equivalents Changes
Cash And Cash Equivalents Changes |
|
In accordance with the recently published financial statements, Rhythm Pharmaceuticals has 235.6 M in Cash And Equivalents. This is 71.3% lower than that of the Biotechnology sector and 47.31% lower than that of the Health Care industry. The cash and equivalents for all United States stocks is 91.28% higher than that of the company.
Rhythm Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Rhythm Pharmaceuticals' direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Rhythm Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Rhythm Pharmaceuticals by comparing valuation metrics of similar companies.Rhythm Pharmaceuticals is currently under evaluation in cash and equivalents category among its peers.
Rhythm Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Rhythm Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Rhythm Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Rhythm Fundamentals
| Return On Equity | -1.48 | ||||
| Return On Asset | -0.46 | ||||
| Profit Margin | (2.30) % | ||||
| Operating Margin | (1.32) % | ||||
| Current Valuation | 3.15 B | ||||
| Shares Outstanding | 61.46 M | ||||
| Shares Owned By Insiders | 0.52 % | ||||
| Shares Owned By Institutions | 99.48 % | ||||
| Number Of Shares Shorted | 6.37 M | ||||
| Price To Book | 307.53 X | ||||
| Price To Sales | 30.65 X | ||||
| Revenue | 77.43 M | ||||
| Gross Profit | 21.5 M | ||||
| EBITDA | (168.46 M) | ||||
| Net Income | (184.68 M) | ||||
| Cash And Equivalents | 235.6 M | ||||
| Cash Per Share | 4.64 X | ||||
| Total Debt | 1.26 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 5.59 X | ||||
| Book Value Per Share | 0.18 X | ||||
| Cash Flow From Operations | (136.16 M) | ||||
| Short Ratio | 9.25 X | ||||
| Earnings Per Share | (4.32) X | ||||
| Price To Earnings To Growth | 0.75 X | ||||
| Target Price | 72.82 | ||||
| Number Of Employees | 226 | ||||
| Beta | 2.09 | ||||
| Market Capitalization | 3.45 B | ||||
| Total Asset | 332.75 M | ||||
| Retained Earnings | (894.74 M) | ||||
| Working Capital | 253.06 M | ||||
| Net Asset | 332.75 M |
About Rhythm Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Rhythm Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Rhythm Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Rhythm Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Rhythm Pharmaceuticals Piotroski F Score and Rhythm Pharmaceuticals Altman Z Score analysis. To learn how to invest in Rhythm Stock, please use our How to Invest in Rhythm Pharmaceuticals guide.You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rhythm Pharmaceuticals. If investors know Rhythm will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Rhythm Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.32) | Revenue Per Share 1.863 | Quarterly Revenue Growth 0.478 | Return On Assets (0.46) | Return On Equity (1.48) |
The market value of Rhythm Pharmaceuticals is measured differently than its book value, which is the value of Rhythm that is recorded on the company's balance sheet. Investors also form their own opinion of Rhythm Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Rhythm Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Rhythm Pharmaceuticals' market value can be influenced by many factors that don't directly affect Rhythm Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Rhythm Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Rhythm Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Rhythm Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.